By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


OncoMed Pharmaceuticals, Inc. 

800 Chesapeake Drive

Redwood City  California  94063  U.S.A.
Phone: 650-995-8200 Fax: 650-298-8600



Start Up

Company News
OncoMed (OMED) Enrolls First Patient In Phase Ib Clinical Trial Of Its Anti-DLL4/VEGF Bispecific Antibody In Patients With Platinum-Resistant Ovarian Cancer 2/13/2017 8:12:53 AM
OncoMed (OMED) Release: Company Initiates Enrollment Of Phase Ib Clinical Trial Of Brontictuzumab For The Treatment Of Metastatic Colorectal Cancer Patients 1/20/2017 7:16:41 AM
OncoMed (OMED) Announces Year-End Cash Balance And 2017 Outlook 1/5/2017 7:46:30 AM
OncoMed (OMED) Initiates Enrollment Of Phase Ib Clinical Trial Of Anti-DLL4/VEGF Bispecific Antibody As Second-Line Treatment For Metastatic Colorectal Cancer Patients 1/4/2017 8:20:12 AM
OncoMed (OMED) Announces Departure Of Chief Medical Officer 12/5/2016 8:20:55 AM
OncoMed (OMED) Presents Initial First-In-Human Data For Anti-DLL4/VEGF Bispecific And Anti-RSPO3 At The 28th EORTC-NCI-AACR Molecular Targets And Cancer Therapeutics Symposium 11/29/2016 8:01:42 AM
OncoMed (OMED) Reports Third Quarter 2016 Financial Results 11/2/2016 8:13:44 AM
OncoMed (OMED) To Report Financial Results For The Third Quarter On Tuesday, November 1, 2016 10/26/2016 8:13:45 AM
OncoMed (OMED) Presents Interim Phase Ib Data For Ipafricept And Vantictumab In Pancreatic Cancer At The ESMO 2016 Congress 10/10/2016 8:45:24 AM
OncoMed (OMED) To Present Clinical Data For Wnt Inhibitors At The ESMO 2016 Congress 9/29/2016 11:32:00 AM